Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain study could pave way for new stroke therapies

NCT ID NCT07423923

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the brain handles two different tasks: finding your way around and remembering daily events, like when you last took medicine. Researchers want to understand what parts of the brain are used for each task and how prior knowledge helps. The goal is to find ways to boost healthy brain function after a stroke or other brain injury. The study involves 15 healthy adults and uses brain scans and memory tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion Criteria (for healthy young adults in fMRI studies) 1. Able to provide verbal and written informed consent 2. Fluent English speaker 3. At least 8th grade education 4. Age between 18-40 years. 5. Normal or corrected-to-normal eyesight Exclusion Criteria (for healthy young adults in fMRI studies) 1. Magnetic resonance imaging contraindications (e.g., metallic objects in body, claustrophobia) 2. Current use of anticonvulsant, neuroleptic, sedatives, or other medications known to affect cognition 3. Neurologic conditions affecting the brain (e.g., stroke, epilepsy, traumatic brain injury with loss of consciousness) 4. Psychiatric conditions (e.g., major depression, schizophrenia) Patient inclusion criteria for iEEG: Inclusion Criteria: 1\. Adult patients with medically refractory epilepsy who are scheduled to undergo or have previously undergone placement of sub-dural electrodes or depth electrodes or stereo-electroencephalography to localize the site of seizure onset. Exclusion Criteria: 1. Patients with gross structural abnormalities (hematoma, tumors, large vascular malformations, diffuse malformations of cortical development) that may impact critical perceptual or memory areas needed to perform tasks. 2. Patients who are unable to participate in memory testing due to impaired cognition or mental retardation. All patients routinely undergo a detailed neuropsychological evaluation, and the neuropsychological report will be used to make this assessment. 3. Patients/volunteers with cardiac pacemakers, intracranial aneurysm clips, or other potentially mobile implanted metallic devices cannot be included in this study, because of possible effects of high power magnetic fields on them. 4. Patients with claustrophobia who cannot undergo an MRI scan without sedation. 5. Pregnant women Patient inclusion criteria for scopolamine: 1. In good general health, aside from a history of epilepsy, as ascertained by medical history, physical examination (PE), clinical laboratory evaluations, and ECG. 2. Body mass index between 18-35 kg/m2. Patient exclusion criteria: 1. History of renal insufficiency. 2. Patients with liver failure. 3. Patients with autoimmune neuropathy. 4. Patients with uncontrolled hyperthyroidism. 5. Patients with a history of dementia. 6. Patient with a history of delirium after using transdermal scopolamine. 7. History of narrow-angle glaucoma (due to increased eye pressure). 8. History of pyloric obstruction or paralytic ileus. 9. History of myasthenia gravis, obstructive uropathy, porphyria, or myasthenia gravis. Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Arizona Psychology Department and Evelyn McKnight Brain Institute

    Tucson, Arizona, 85721, United States

  • University of Texas Southwestern Medical Center / O'Donnell Brain Institute

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.